Swedish Orphan Biovitrum Ab · OMXSTO:SOBI
Swedish Orphan Biovitrum Ab — Shareholder Meeting (May 2020)
12 slides from Swedish Orphan Biovitrum Ab's shareholder meeting presentation, May 13, 2020
Slide 1: AGM 2020 CEO presentation
AGM 2020 CEO presentation May 13, 2020
Slide 2: Forward looking statements
Forward looking statements In order to utilise the ‘Safe Harbor’ provisions of the United States Private Securities Litigation Reform Act of 1995, Swedish Orphan Biovitrum AB (publ) is providing the following cautionary statement. This presentation contains forward-looking statements with respect to
Slide 3: Taking charge in a challenging environment
Taking charge in a challenging environment… 2 Take care of patients Secure supply for all key products, respond to increased demand in a flexible way 1 Protect team Early travel restrictions, enable a virtual office environment whenever possible Continue access Interactions with health care professi
Slide 4: Creating a rare disease leader
Creating a rare disease leader Expand Expand Strengthen Grow within within geographic late-stage Immunology Haematology footprint pipeline Transformation into First launch success with Step-change towards Investing in a sustainable broader Haematology Gamifant, solid growth of North America and port
Slide 5: Strong performance in 2019 and Q1 2020
Strong performance in 2019 and Q1 2020 Total revenue (SEK M) Q1 Q1 Full-year 5 000 Amounts in SEK M 2020 2019 Change 2019 Total revenue 4,639 3,265 42% 14,248 4 000 Gross profit 3,598 2,494 44% 10,913 Gross margin1 78% 76% 77% EBITA adjusted1,2 2,173 1,471 48% 6,145 3 000 EBITA margin adjusted1,2 47
Slide 6: Evolution towards building a strong second leg in Immunology
Evolution towards building a strong second leg in Immunology Q1 sales breakdown over last three years SEK M 39% Specialty Care 34% 4,639 Immunology Haematology 445 15% 3,265 1 800 434 1,964 1 100 445 297 2 394 1 731 1 222 Q1 2018 Q1 2019 Q1 2020 6
Slide 7: Q1 2020: Strong start to year despite challenging period
Q1 2020: Strong start to year despite challenging period Q1 2020 report Immunology: 57% growth at CER year on year • Kineret: Strong acceleration in growth due to COVID-19 +39% CER Strong demand… • Synagis: Uplift on continued execution and seasonal demand +72%1 CER Revenue Q1, SEK M • Gamifant: Acc
Slide 8: Sustainability strategy
@sobl Sustainability strategy GOOD HEALTH ‘AND WELL-BEING yj 1 RESPONSIBLE CONSUMPTION ‘AND PRODUCTION & Commitment to patients GO Access to treatment psy Ethical and responsible behaviour 1 PARTNERSHIPS FOR THE GOALS @ 7 Safety for patients and environment
Slide 9: Our portfolio is well positioned for the future
Our portfolio is well positioned for the future Best in class EHL Elocta; BIVV001 Continuing to grow market share, headroom Phase 3 Q1: +35% vs. PY Alprolix Best in class EHL BIVV002 Haematology Pipeline Q1: +41% vs. PY Strong comparative data Pre-clinical Doptelet Strong trajectory Indication Q1: 6
Slide 10: Continued strong operating cash flow in Q1 2020, leverage < 2.5x
Continued strong operating cash flow in Q1 2020, leverage < 2.5x Net debt (SEK M) Q1 2020 update -1.2B 16 000 • Operating cash flows of 2B SEK 12 000 • Net debt reduction of -1.2B SEK • Leverage < 2.5x 8 000 • Available liquidity of ~7B SEK 4 000 0 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Acquisition
Slide 11: ….enabling continued growth
….enabling continued growth Doptelet and Gamifant Investments in market penetration and clinical studies Doptelet and Gamifant have potential peak sales beyond USD 500 M each Mid-term outlook Continuous annual double-digit growth in Haematology and Immunology in the mid-term 11
Slide 12: Sobi is a trademark of Swedish Orphan Biovitrum AB (publ)
Sobi is a trademark of Swedish Orphan Biovitrum AB (publ). © 2020 Swedish Orphan Biovitrum AB (publ) – All rights reserved Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm • Sweden www.sobi.com
Swedish Orphan Biovitrum AB (Sobi) — Shareholder Meeting (May 2020) on 6ix